As increasing attention turns to microbiome-based therapeutics, the Scottish biotech Enterobiotix has closed a Series A fundraising to potentially treat a myriad of medical conditions by improving gut health.
Last week, EnteroBiotix raised €18M (£15.5M) in Series A funding to further develop a pill to restore the patient’s gut microbiome to a healthy state using stool samples from healthy donors. The technology could potentially tackle a plethora of seemingly unrelated diseases, including infections, metabolic disorders, and cancer.
The Scottish investment firm Thairm Bio led the financing, with US-based Kineticos Ventures joining existing investors including SIS Ventures and Scottish Enterprise, Scotland’s national economic development agency.
This is the latest example of increasing interest in the human microbiome — the ecosystem of viruses, bacteria, and other microbes in and on the body — and its potential to treat a wide range of conditions including cancer, diabetes, Covid-19, and depression.
“The microbiome is now considered a key area for innovative healthcare, and we believe that the momentum is growing,” said Hervé Affagard,
The post UK Startup Surfs Investment Wave in Microbiome with €18M Series A appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.